Unraveling the biology of ME/CFS and long COVID

ME/CFS, long COVID and related condition are deeply complex with many different causes and risk factors. On this page, we've collated the published findings, videos, news and blogs from our ME/CFS and long COVID research.

In over 30 years of research into ME/CFS and intense global efforts to understand the biological mechanisms of long COVID, not a single replicable genetic finding had been reported for either, until now.

Our researchers have, for the first time, identified genetic mechanisms causing ME/CFS and long COVID and used this to apply a precision medicine approach - stratifying patients into sub-groups who will likely benefit from targeted treatments.

We’re currently confirming our results in much larger, better characterized patient populations:

• For long COVID we've achieved the first ever reproduction of genetic associations using the All of Us study data as part of a collaboration with Metrodora Foundation.
• For ME/CFS we're using the DecodeME study data as part of the LOCOME (Long Covid and ME) grant.

We're now conducting research to:

1. Validate rapid non-invasive tests to detect risks and identify causes of ME/CFS and long COVID in patients
2. Identify actively protective biology that may prevent people getting ME/CFS and long COVID and aid recovery
3. Identify and validate drug candidates that may be able to treat ME/CFS, long COVID and related conditions

Published research
Reproducibility of Genetic Risk Factors Identified for Long COVID using Combinatorial Analysis Across US and UK Patient Cohorts with Diverse Ancestries	Identifying Genetic Risk Factors for ME/CFS and Long COVID  Poster detailing our discovery of the first genetic associations, novel targets, actively protective biology, and diagnostics.
Genetic Risk Factors for ME/CFS Identified using Combinatorial Analysis	Genetic Risk Factors for Severe and Fatigue Dominant Long COVID and Commonalities with ME/CFS Identified by Combinatorial Analysis

Video presentations
Genomics and Genetic Susceptibilities of ME Presented at the NIH ME/CFS Research Roadmap Webinar 2024	Precision Medicine for Long COVID and ME/CFS Presented at the Unite to Fight ME Conference 2024

 

The Causal Biology of ME Presented at the Invest in ME Research Congress 2024

 

 

News announcements
PrecisionLife and Metrodora Foundation announce confirmation of key genetic findings for long COVID across diverse populations	PrecisionLife and Metrodora Institute share first insights with ME/CFS, Long COVID participants in MetX study
Precision Medicine Clinical Trials Lunched for ME/CFS and Long Covid to Accelerate Diagnosis and Treatment	PrecisionLife Project Awarded Innovate UK Grant to Improve Diagnosis and Treatment of ME/CFS and Long Covid

 

 

Blogs
How new research confirmed long COVID genetic associations for diagnostics and treatments	New Study Links 14 Genes to ME/CFS By Simon McGrath for the ME/CFS Research Review

Partners

Datasets

About PrecisionLife

PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex chronic diseases, which affect over 5 billion patient lives and account for over 80% of healthcare spending.

Our unique AI-led combinatorial analytics platform is unparalleled in its ability to identify causal disease biology – revealing the underlying drivers of many diseases for the first time, linking individuals to the treatments that will benefit them most, and accurately predicting lifetime risk of disease.

PrecisionLife’s precision medicine insights and diagnostic tools hold the key to reducing the global burden of chronic diseases, improving the rate of successful drug development, and increasing healthspan for billions of people.

Contact us via the form below to find out more about partnering with PrecisionLife.